GSK TO LICENCE ROCHE CARDIAC DRUG FOR INDIA

GlaxoSmithKline Pharmaceuticals Ltd is planning to in-licence cardiovascular drug, Carvedilol, of Swiss pharmaceuticals major Roche for the Indian market. Carvedilol is the first beta blocker to have improved survival in a wide spectrum of heart failure patients. In India, the total market for Carvedilol is pegged at Rs 16.6 crore of the Rs 430 crore cardiovascular segment.

Algorum (http://www.algorum.com/articles/articles.asp?id=1870§ion=Pharma)